Format

Send to

Choose Destination
Blood. 2015 Mar 26;125(13):2095-100. doi: 10.1182/blood-2014-07-587964. Epub 2015 Jan 30.

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.

Author information

1
Laboratory for Genomics in Myeloma, Institut Universitaire du Cancer and University Hospital, Toulouse, France; Centre de Recherche en Cancérologie de Toulouse INSERM U1037, Toulouse, France;
2
Unité Mixte de Génomique du Cancer, University Hospital, Nantes, France; INSERM U892, Nantes, France;
3
Service d'Epidémiologie, University Hospital, Toulouse, France;
4
Hematology Department, University Hospital, Dijon, France;
5
Hematology Department, University Hospital, Nancy, France;
6
Hematology Department, University Hospital, Lille, France;
7
Hematology Department, University Hospital, Bordeaux, France;
8
Hematology Department, University Hospital, Lyon, France;
9
Hematology Department, University Hospital, Toulouse, France;
10
Hematology Department, Institut Paoli-Calmettes, Marseille, France;
11
Hematology Department, Henri Mondor University Hospital, Créteil, France;
12
Hematology Department, General Hospital, Chalon sur Saone, France;
13
Hematology Department, Saint-Antoine University Hospital, Paris, France;
14
Hematology Department, University Hospital, Caen, France;
15
Hematology Department, University Hospital, Nantes, France; and.
16
LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Abstract

In multiple myeloma, cytogenetic changes are important predictors of patient outcome. In this setting, the most important changes are deletion 17p, del(17p), and translocation of chromosomes 4 and 14, t(4;14), conferring a poor outcome. However, a certain degree of heterogeneity is observed in the survival of these high-risk patients. We hypothesized that other chromosomal changes may impact the outcome. We retrospectively analyzed a large series of 242 patients displaying either t(4;14) (157 patients) or del(17p) (110 patients), 25 patients presenting both abnormalities, using single nucleotide polymorphism array. In patients with t(4;14), del(1p32), del22q, and >30 chromosomal structural changes negatively impacted progression-free survival (PFS). For overall survival (OS), del(13q14), del(1p32), and the number of chromosomal structural changes worsened the prognosis of patients. For patients with del(17p), del6q worsened the prognosis of patients, whereas trisomy 15 and monosomy 14 were found to have a protective effect on PFS. For OS, del(1p32) worsened the prognosis of patients, whereas having >8 numerical changes was found to have a protective effect on survival. This study, which is the largest series of high-risk patients analyzed with the most modern genomic technique, identified 1 main factor negatively impacting survival: del(1p32).

PMID:
25636340
PMCID:
PMC4375107
DOI:
10.1182/blood-2014-07-587964
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center